Clinical trials: 5-Fluorouracil
Colorectal Cancer
A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.
This 2 arm study will compare the resection rate of liver metastases and safety of surgery in patients with metastatic colorectal cancer and primarily unresectable liver metastases receiving treatment with Avastin in combination…
- Trial name
- NCT00778102
- Testing
- 5-FU, Irinotecan, Leucovorin
- Where
- 19 sites in Austria, France and 2 more
- Volunteers
- 80 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer, Chemotherapy-induced Neutropenia
Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer
The primary objective of this study is to assess the efficacy of monosialotetrahexosylganglioside (GM1) for preventing oxaliplatin induced neurotoxicity in colorectal cancer patients who received oxaliplatin-based adjuvant…
- Trial name
- NCT02251977
- Testing
- GM1, mFOLFOX6 or XELOX
- Where
- China
- Volunteers
- 196 people
- Sponsor
- Yuhong Li
Ovarian Carcinoma, Relapse
A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma
This is a Phase II study for recurrent ovarian carcinoma platinum-sensitive and resistant tumors Folfox regimen.
- Trial name
- NCT01481701
- Testing
- Oxaliplatin
- Where
- Belgium
- Volunteers
- 90 people
- Sponsor
- Jules Bordet Institute
Colorectal Cancer
Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as ursodiol, oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00873275
- Testing
- bevacizumab, FOLFOX regimen, fluorouracil
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- City of Hope Medical Center
High-Risk Non-Muscle Invasive Bladder Cancer
A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calmette-Guerin Therapy for High-risk Non-muscle Invasive Bladder Cancer.
In the UK 20,000 people develop urothelial bladder cancer each year with 75-80% having Non-Muscle Invasive Bladder Cancer (NMIBC).
- Trial name
- TRAIN (NCT07268339)
- Testing
- radiotherapy, BCG
- Where
- United Kingdom
- Volunteers
- 328 people
- Sponsor
- The Christie NHS Foundation Trust
Metastatic Colorectal Cancer
Nitazoxanide in Patients With Metastatic Colorectal Cancer
The aim of this study is to evaluate the potential efficacy and safety of nitazoxanide in patients with metastatic colorectal cancer.
- Trial name
- NCT06049901
- Testing
- Nitazoxanide
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Tanta University
Colorectal Cancer, Chemotherapy Effect
Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients
The goal of this clinical trial] is to compare in resectable stage T3-4N2 colorectal cancer. The main question it aims to answer is: whether the use of targeted therapy in combination with adjuvant chemotherapy is associated with…
- Trial name
- NCT05797467
- Testing
- FOLFOX chemotherapy regimens, Bevacizumab
- Where
- China
- Volunteers
- 366 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Organ Preservation, Rectal Cancer Stage I
Total Neoadjuvant Therapy With Additional Consolidation Chemotherapy Followed by Local Excision Versus Total Neoadjuvant Therapy Followed by Local Excision at Stage I Rectal Cancer
Safety and Efficacy of Organ Preservation Treatment for Stage I Rectal Cancer: Optimization of Consolidation Chemotherapy Before Local Excision After Neoadjuvant Chemoradiotherapy (OPTION); A Multi-center, Prospective, Randomized…
- Conditions
- Organ Preservation, Rectal Cancer Stage I, Total Neoadjuvant Treatment, Consolidation Therapy
- Trial name
- OPTION (NCT07563907)
- Testing
- TNT with additional consolidation chemotherapy followed by local excision, TNT followed by local excision
- Where
- South Korea
- Volunteers
- 292 people
- Sponsor
- Seoul National University Hospital
Rectal Cancer
Adjuvant Chemotherapy After Preoperative Chemoradiotherapy to Treat Rectal Cancer
The purpose of this study is to evaluate the disease-free survival in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy with fluoropyrimidines and surgery followed by adjuvant combination…
- Trial name
- NCT00807911
- Testing
- Adjuvant FL, Adjuvant FOLFOX
- Where
- 6 sites in South Korea
- Volunteers
- 322 people
- Sponsor
- Asan Medical Center
Breast Cancer
Weekly Docetaxel and CMF in the Adjuvant Treatment of Elderly Women With High-Risk Breast Cancer
This trial will evaluate the effectiveness of standard adjuvant treatment with CMF chemotherapy versus treatment with weekly docetaxel in patients with high-risk breast cancer who are 65 years of age and older or are poor…
- Trial name
- NCT00193011
- Testing
- Docetaxel, Cyclophosphamide, Methotrexate
- Volunteers
- 150 people
- Sponsor
- SCRI Development Innovations, LLC
Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
This phase III trial studies how well chemotherapy and radiation therapy work with or without atezolizumab in treating patients with localized muscle invasive bladder cancer.
- Conditions
- Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
- Trial name
- NCT03775265
- Testing
- Atezolizumab, Biopsy of Bladder, Cisplatin
- Where
- 365 sites in United States
- Volunteers
- 475 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Carcinoma
FOLFIRI Versus Irinotecan as Second-line Treatment in Metastatic Colorectal Cancer Patients
This study is designed to compare the efficacy and safety of FOLFIRI regimen with irinotecan monodrug in the treatment of advanced colorectal cancer patients in the second-line setting.
- Trial name
- NCT02935764
- Testing
- Irinotecan, 5-fluorouracil, Leucovorin
- Volunteers
- 164 people
- Sponsor
- Fudan University
Metastatic Breast Cancer
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
Open label multicentric phase II randomized trial, using high throughput genome analysis as a therapeutic decision tool, which aims at comparing a targeted treatment administered according to the identified molecular anomalies of…
- Trial name
- SAFIR02_Breast (NCT02299999)
- Testing
- AZD2014, AZD4547, AZD5363
- Where
- 25 sites in France
- Volunteers
- 1,460 people
- Sponsor
- UNICANCER
Colorectal Cancer, Peritoneal Metastases
Intraperitoneal Irinotecan With Concomitant FOLFOX and Bevacizumab
The rationale of the current study is that the addition of intraperitoneal irinotecan (75 mg) to palliative systemic therapy is feasible and safe, and might result in an increased overall and progression free survival in patients…
- Trial name
- INTERACT-II (NCT06003998)
- Testing
- Irinotecan, FOLFOX regimen, Bevacizumab
- Where
- 2 sites in Netherlands
- Volunteers
- 85 people
- Sponsor
- Catharina Ziekenhuis Eindhoven
Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Fluorouracil and Low-Dose Suramin as Chemosensitization in Treating Patients With Metastatic Renal Cell (Kidney) Cancer
Drugs used in chemotherapy, such as fluorouracil, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00083109
- Testing
- Fluorouracil, Pharmacological Study, Suramin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer, Salvage Radiotherapy
Simultaneous Integrated Boost for Mediastinal Lymph Node Recurrence After Radical Surgery of Esophageal Cancer
Esophageal cancer (EC) ranks the seventh most diagnosed malignant tumor (572,000 new cases) and the sixth cancer-related mortality (509,000 deaths) worldwide in 2018.
- Conditions
- Esophageal Cancer, Salvage Radiotherapy, Dose-escalation, Mediastinal Lymph Node Recurrence
- Trial name
- NCT03990532
- Testing
- treatment group(phase I), treatment group (phase II)
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Ruijin Hospital
Metastatic Colorectal Cancer
Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors
To analyze the pathological tumor response on resected colorectal cancer metastases after preoperative treatment with cetuximab combined with FOLFOX or FOLFIRI regimen in a prospective cohort (RAS and B-RAF WT tumors) and to…
- Trial name
- NCT01858662
- Testing
- Metastases Resection ( multiple steep surgery possible), 5-Fluorouracile, leucovorin L
- Where
- 7 sites in Belgium
- Volunteers
- 4 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Advanced and Metastatic Breast Cancer
PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast Cancer
This trial is an open, multi-center, phase Ic clinical study on the pharmacokinetics and drug interactions of utidelone injection combined with capecitabine in patients with recurrent and metastatic breast cancer.
- Trial name
- NCT05052437
- Testing
- Utidelone Injection; capecitabine, Utidelone
- Where
- 2 sites in China
- Volunteers
- 16 people
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
Cancer
A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)
To characterize the safety profile of ARGX-110 administered as mono- or combination therapy to patients with NPC at various stages of its natural history (adjuvant vs. metastatic).
- Trial name
- NCT02759250
- Testing
- ARGX-110
- Where
- Belgium
- Volunteers
- 11 people
- Sponsor
- argenx
Colorectal Cancer, Gastroesophageal Cancer
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
This study will determine the pharmacodynamically-active dose of gevokizumab and the tolerable dose of gevokizumab in combination with the standard of care anti-cancer therapy in patients with metastatic colorectal cancer…
- Conditions
- Colorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma
- Trial name
- NCT03798626
- Testing
- Gevokizumab, Bevacizumab, Modified FOLFOX6
- Where
- 34 sites in United States, Australia and 13 more
- Volunteers
- 167 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.